IP Library Granted Patent US 8,853,166
Granted Patent B2
US 8,853,166 · App. 12/433,345 · Granted Oct 7, 2014

Neurotrophic factor MANF and uses thereof

Inventors: Mart Saarma (Helsinki, FI); Päivi Lindholm (Vantaa, FI); Merja Voutilainen (Helsinki, FI); Johan Peränen (Helsinki, FI); Raimo Tuominen (Vantaa, FI); Mikko Airavaara (Annapolis, MD); Veli-Matti Leppänen (Otalampi, FI); Maria Lindahl (Espoo, FI); Jaan-Olle Andressoo (Helsinki, FI)
Assignee: Herantis Pharma PLC.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,853,166
App. No.
12/433,345
Granted
Oct 7, 2014
Kind
B2
Abstract

The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.

Claims (6)

1. A method of treatment of an individual having Parkinson's disease, said method comprising:

administering by directly injecting a therapeutically effective amount of an expression vector to the central nervous system of the individual having Parkinson's disease,

wherein said vector comprises a promoter sequence capable of directing the expression of an operably linked polynucleotide in a mammalian cell,

wherein said polynucleotide encodes a polypeptide having SEQ ID NO:2 or a functional fragment thereof,

wherein said polypeptide is a mesencephalic astrocyte-derived neurotrophic factor (MANF) polypeptide, and

wherein said functional fragment is a MANF polypeptide having SEQ ID NO:4 and is capable of preventing the 6-hydroxydopamine (6-OHDA)-induced degeneration of dopaminergic neurons.

Assignments (4)
CHANGE OF NAME Recorded Aug 5, 2014
From: HERMO PHARMA LTD.
To: HERANTIS PHARMA PLC.
Reel/Frame 033474/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2010
From: LICENTIA LTD.
To: HELSINGIN YLIOPISTON RAHASTOT
Reel/Frame 025463/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2010
From: HELSINGIN YLIOPISTON RAHASTOT
To: HERMO PHARMA LTD.
Reel/Frame 025463/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2009
From: SAARMA, MART; LINDHOLM, PAIVI; VOUTILAINEN, MERJA; PERANEN, JOHAN; TUOMINEN, RAIMO; AIRAVAARA, MIKKO; LEPPANEN, VELI-MATTI; LINDAHL, MARIA; ANDRESSOO, JAAN-OLLE
To: LICENTIA LTD.
Reel/Frame 022959/0716 →
Continuity (2)
Provisional Application 61052757 · May 13, 2008
Related Publication 20090282495A1 · Nov 12, 2009